The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Abstract
Background/Objectives: Chronic constipation is a prevalent gastrointestinal (GI) disorder among individuals with diabetes mellitus (DM), occurring more often than in healthy subjects. This review provides a systematic overview of this often-underestimated clinical condition in people with DM. Methods: A narrative review of literature up to 30 May 2025 was conducted, focusing on studies regarding the pathogenesis of constipation in DM, the correlation with GLP-1 RAs treatment, and the diagnostic-therapeutic framework. Results: The mechanisms underlying constipation in DM remain largely unclear; however, a multifactorial etiology has been proposed, involving structural changes in various tissues within the GI tract wall, as well as functional abnormalities, often secondary to hyperglycemia. It is noteworthy that the use of GLP-1 RAs, a class of medications crucial for managing glycemic control and reducing cardiovascular and renal risk in type 2 DM, is another cause of constipation. The diagnosis of constipation is typically based on clinical evaluation, as validated methods for assessing colonic transit are invasive and available only in specialized centers. Treatment objectives include alleviating symptoms and restoring bowel function. The primary strategy for management involves dietary changes and physical activity. If the clinical response is inadequate, the use of laxatives is recommended. Finally, newer agents and mechanical methods may be considered for scenarios that are particularly severe. Conclusions: Given the increasing global prevalence of DM, healthcare professionals must recognize the clinical problem constituted by the occurrence of chronic constipation, especially considering the use of medications such as GLP-1 RAs that may induce this clinical condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, data from the FDA Adverse Event Reporting System indicate a lower incidence of nausea and vomiting, potentially due to GIP receptor-mediated neuronal inhibition in the area postrema [149,150], whereas constipation appears more frequent, with the underlying mechanisms yet to be fully elucidated [151].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [151]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults
Larsen, N., Vogensen, F. K., van den Berg, F. W. J., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009085 · Cited by 2,952
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866 · cited 1×
“%) of defecations; (e) fewer than three spontaneous bowel movement (SBM) per week; (f) loose stools rarely present without the use of laxatives; and (g) insufficient criteria for irritable bowel syndrome [9].”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“Moreover, certain GLP-1 RAs, such as liraglutide, dulaglutide, and semaglutide in both formulations, have demonstrated CV and renal benefits [66–68].”
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 3×
“Moreover, certain GLP-1 RAs, such as liraglutide, dulaglutide, and semaglutide in both formulations, have demonstrated CV and renal benefits [66–68].”
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“POMC/CART neurons that express GLP-1 receptors activate PB neurons and directly or indirectly suppress NPY/AgRP neurons [69,70], leading to disinhibition of suppressive signals to the PB.”
Epidemiology of constipation in children and adults: A systematic review
Mugie, S. M., Benninga, M. A., & Di Lorenzo, C. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.12.010 · Cited by 941
American Gastroenterological Association Technical Review on Constipation
Bharucha, A. E., Pemberton, J. H., & Locke, G. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.028 · Cited by 909 · cited 1×
“It is even more prevalent among older adults and those with lower socioeconomic status [12].”
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“POMC/CART neurons that express GLP-1 receptors activate PB neurons and directly or indirectly suppress NPY/AgRP neurons [69,70], leading to disinhibition of suppressive signals to the PB.”
Disorders of gastrointestinal motility associated with diabetes mellitus
FELDMAN, M., & SCHILLER, L. R. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-3-378 · Cited by 653 · cited 1×
“The prevalence of constipation is greater in individuals with DM compared to the general population: in a study on 136 subjects [13], almost 60% had constipation symptoms, whereas other studies have found a prevalence ranging from 11 to 56% [14,15].”
Bytzer, P., Talley, N. J., Leemon, M., Young, L. J., Jones, M. P., & Horowitz, M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.16.1989 · Cited by 632
Cited by
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“…from the FDA Adverse Event Reporting System indicate a lower incidence of nausea and vomiting, potentially due to GIP receptor-mediated neuronal inhibition in the area postrema [149,150], whereas constipation appears more frequent, with the underlying mechanisms yet to be fully elucidated [151].”
Self-citationZhou, X., You, G., Zhang, L., Fan, D., & Yue, C. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-026-10741-2 · Cited by 1
Shao, M., Zhu, T., Hu, X., Fang, X., Pan, X., Wen, L., Dai, P., Amdanee, N., Zhang, L., Xu, Y., et al. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261432764
“Diabetic enteropathy or enteric neuropathy that affects colonic transit has been associated with both diarrhea and constipation, 91–93 which might independently contribute to or modify the presentation of AIC.”
Elmezayen, Z. W., Qrareya, F., Abdallah, A., Salameh, H., & Qaisi, W. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261443862
“20 Another key implication highlighted by this case is the importance of maintaining adequate caloric and protein intake during rapid weight loss induced by GLP-1 receptor agonists.”
Kurniasari, A. F., & Susanti, N. (2026) · Indonesian Journal of Case Reports
Metadata
- Authors
- De Fano, M., Baluganti, S., Manco, M., Porcellati, F., Fanelli, C. G., & Bassotti, G.
- Affiliations
- Endocrine and Metabolic Sciences Section, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy
- University of Perugia (IT)
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2025-09-24
- Volume
- 17
- Issue
- 19
- Pages
- 3038
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12526187
- OpenAlex
- W4414480209
- Cited by
- 4
- References
- 114
- Citations by year
- 2026: 3 · 2025: 1
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- chronic constipation, diabetes mellitus, GLP-1 receptor agonists, type 2 diabetes, hyperglycemia, colonic transit, laxatives
- MeSH terms
- Colon, Constipation, Diabetes Mellitus, Type 2, Gastrointestinal Motility, Humans, Diabetes Complications, Glucagon-Like Peptide 1, Laxatives
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus. https://app.cochat.ai/papers/10.3390/nu17193038
- The paper
- De Fano, M., Baluganti, S., Manco, M., Porcellati, F., Fanelli, C. G., & Bassotti, G. (2025). The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus. Nutrients. https://doi.org/10.3390/nu17193038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

